ABSTRACT
BACKGROUND Delhi is hyperendemic for dengue virus (DENV) where all the four DENV have been previously reported. A constant vigilance of circulating dengue virus serotypes is important in surveillance, since the introduction of a new variant to areas affected by pre-existing serotypes constitutes a risk factor for DHF and Dengue Shock Syndrome.
OBJECTIVES This retrospective study was carried out with an objective to determine the circulating serotype and genotype of Dengue virus in acute phase blood samples of patients who reported to a tertiary liver care hospital in New Delhi during the last two years (2017 – 2018).
METHODS The data of clinician-initiated testing for dengue NS1 antigen was searched in the institutional hospital information system. The serum sample of dengue NS1 antigen positive cases confirmed by ELISA (PANBIO, Gyeonggi-do, ROK) and a fever duration of less than 5 days were retrieved from the laboratory archive. The dengue virus serotyping on these sample were carried out by reverse transcriptase PCR. Sequencing and phylogenetic analysis was done for the capsid-pre membrane (CPrM) region to determine the genotype.
RESULTS A total of 440 acute-phase samples were received. Twenty one(4.77%) were positive for dengue NS1 antigen with a mean age of 35.1 years and male to female ratio of 1.1:1. Eight cases (38.09%) were positive by Dengue RT-PCR and all belonged to DENV-3 serotypes. Phylogenetic tree analysis revealed DENV-3 clustered to genotype III with 100% homology with 2008 Indian subcontinent strain.
CONCLUSION This study revealed that the present circulating dengue virus serotype in Delhi is DENV–3 genotype III. It is similar to previously isolated 2008 Indian subcontinent strain suggesting neither any change in serotype nor any further evolution of DENV-3. That explains the present relatively stable dengue endemicity in Delhi NCR.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
None
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data has been taken from our hospital information system
